Analysis
Consonance Capital Partners closed its third healthcare-focused private equity fund at a $1.35 billion hard cap in a heavily oversubscribed process, according to a Business Wire release dated October 9. The firm said the raise took under four months from launch to final close.
The new fund continues a steady progression for the firm. Consonance's debut fund closed at a $500 million hard cap. Its second fund, closed in April 2020, raised a further step up from there, according to prior reporting on the firm's fundraising history. Fund III is roughly 1.6 times that second vehicle's size six years later, a growth rate at the high end of the broader healthcare PE market's typical fund-over-fund step-up of 20-40%.
“Its second fund, closed in April 2020, raised a further step up from there, according to prior reporting on the firm's fundraising history.”
Consonance targets lower-middle-market healthcare companies generating between $20 million and $150 million in revenue -- a niche distinct from both the large-cap hospital and insurance roll-ups pursued by firms like KKR and Blackstone, and the venture-stage digital health startups chasing AI-driven clinical tools. That positioning has let Consonance avoid direct competition with both the mega-funds and the AI-native healthtech names, such as General Medicine and Healthleap, that have dominated recent funding headlines with venture-style rounds rather than buyout capital.
An under-four-month close for a fund substantially larger than its predecessor signals strong limited-partner demand for healthcare-specific exposure at a moment when public healthcare equities have lagged broader indices and investors are rotating toward defensive, non-cyclical sectors. It also arrives the same week Spectrum Equity closed its own largest-ever growth-equity fund and Union Square Ventures raised fresh capital across two vehicles, suggesting institutional capital is re-committing across multiple private-markets strategies simultaneously, not only to AI-labeled vehicles chasing speculative markups.
What the announcement doesn't disclose is deployment pace or specific target sectors within healthcare for Fund III -- details that will likely surface as Consonance announces its first platform acquisitions from the new vehicle in the coming months.